Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear? + a private exchange
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions? + a private exchange
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test? + a private exchange
- 6 If one digoxin result is 2.65 nmol/L at 3 hours 52 minutes after a dose and another is 1.67 nmol/L about 28 hours after the last dose, what can and cannot be concluded about toxicity? + a private exchange
- 7 Is “no clear indication” sufficient reason to abruptly stop digoxin after 30 years of use, or should the original indication and current cardiac condition first be established? + a private exchange
- 8 If digoxin is stopped in an elderly patient who remains on metoprolol, what monitoring should be done afterward to detect worsening heart failure or loss of rate control? + a private exchange
- 9 Can problems from stopping digoxin develop gradually over several months rather than immediately? + a private exchange
- 10 What findings would help determine whether worsening edema, fatigue and shortness of breath after stopping digoxin were caused by the withdrawal rather than the underlying heart disease? + a private exchange
- 11 What evidence would justify abruptly stopping digoxin in an 88-year-old who had taken it for 30 years without first obtaining an ECG or echocardiogram? + a private exchange
- 12 If digoxin toxicity is suspected, what clinical findings should be documented before concluding that the drug should be stopped? + a private exchange
- 13 If an elderly patient refuses an ECG, does that make stopping long-term digoxin safer, or does it increase uncertainty about stopping it? + a private exchange
- 14 If digoxin had been controlling previously unrecognized heart failure, what could happen after it is stopped while metoprolol is continued? + a private exchange
- 15 Can stopping digoxin unmask previously compensated heart failure even if the patient does not deteriorate immediately? + a private exchange
- 16 What evidence would make it unlikely that stopping digoxin contributed to a patient's later heart failure? + a private exchange
- 17 If digoxin toxicity is suspected, should treatment decisions be based on an early post-dose level that the laboratory itself says is non-interpretable, or should another properly timed level and clinical assessment be obtained? + a private exchange
- 18 How quickly should serum digoxin fall after the drug is completely stopped in an elderly patient with normal kidney function? + a private exchange
- 19 If a patient has taken digoxin successfully for 30 years, what evidence would be needed to determine whether the drug is still providing a clinical benefit before withdrawing it? + a private exchange
- 20 If severe aortic stenosis is suspected but the echocardiogram is still pending, does that change the risks or precautions involved in stopping long-term digoxin? + a private exchange
- 21 What should be documented when a physician tells an elderly patient to stop long-term digoxin? + a private exchange
- 22 Can a physician safely tell a patient to stop digoxin without notifying the dispensing pharmacist? If so, what safeguards are needed? + a private exchange
- 23 n an elderly patient who had taken digoxin continuously for approximately 30 years, if the physician decides to stop it but the original indication is uncertain and an echocardiogram is still pending, what clinical follow-up during the first days, weeks, and months would help determine whether withdrawal is causing loss of previously compensated cardiac function?
- 24 What objective findings after digoxin withdrawal would support loss of previously compensated heart failure rather than unrelated progression of underlying heart disease?
- 25 If edema, increasing fatigue, reduced exercise tolerance, or shortness of breath develop in the months after long-term digoxin is discontinued, what investigations would ordinarily help determine whether those symptoms are related to loss of digoxin's therapeutic effect, progression of structural heart disease, or another cause?
- 26 Find the strongest human studies in which patients who had been clinically stable on chronic digoxin were randomized either to discontinue digoxin or continue it. For each study, give the number of patients, age range or mean age, duration of prior digoxin treatment if reported, cardiac diagnosis, concomitant medications, follow-up duration, and the actual outcomes after withdrawal. Do not extrapolate beyond what the studies measured.
- 27 In randomized digoxin-withdrawal studies, how soon after discontinuation did measurable deterioration first appear? Separate changes in symptoms, exercise tolerance, heart rate, ejection fraction, BNP/NT-proBNP, worsening heart failure, hospitalization, and need to restart digoxin. Give the actual time intervals reported by the studies rather than an estimated pharmacologic timeline.
- 28 In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
Answered on this page ↓
In digoxin-withdrawal trials, did every patient deteriorate immediately after stopping, or did some patients remain apparently stable initially and deteriorate later? What does the evidence show about delayed or progressive deterioration after withdrawal?
The short version: the evidence does not show whether deterioration is immediate or delayed, because the trials measured outcomes at a single late time point, not continuously.
The 2015 study measured BNP and walk distance at 12 weeks after withdrawal [1]. The PROVED and RADIANCE trials from 1993 reported the proportion of patients who worsened over the entire follow-up period, but did not give a day-by-day or week-by-week breakdown [1]. None of these studies tracked patients in the first days or weeks after stopping digoxin. So the question of whether some patients remain stable initially and then deteriorate later cannot be answered from this evidence.
What the evidence does show is that at 12 weeks, the group that stopped digoxin had worse BNP (405 to 604 ng/L, p=0.02) and shorter walk distance (474 to 455 meters, p=0.02) than the group that stayed on it [1]. But this is a single snapshot. It does not tell you whether the deterioration happened in the first week, the fourth week, or the tenth week. A patient could have been stable for weeks and then worsened, or could have worsened immediately and stayed worse. The study design cannot distinguish.
The 1995 economic analysis and the 1996 review confirm that withdrawal leads to more hospitalizations and worsening heart failure [2, 3], but again, neither gives a time course. The systematic review from 2014 covers RAAS inhibitors and beta-blockers, not digoxin [4].
My call: the evidence does not answer whether deterioration after digoxin withdrawal is immediate or delayed. The trials measured outcomes at a single late time point (12 weeks) and did not track the first days or weeks. A study that measured patients at 1, 2, 4, and 8 weeks after withdrawal would settle the question. Confidence: low.
Sources used 4
-
Digoxin withdrawal in patients with stable heart failure receiving optimal contemporaneous therapy worsens heart failure status but better preserves quality of life
This study investigates the effects of digoxin withdrawal in patients with stable heart failure receiving optimal therapy, finding that withdrawal worsens heart failure status but may improve quality of life.
DOI: 10.1016/j.hlc.2015.06.217 -
Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure
This study analyzes the health and economic outcomes of continuing versus withdrawing digoxin therapy in U.S. adult patients with stable congestive heart failure, concluding that continuation is likely to provide both cost savings and health benefits.
DOI: 10.1016/0735-1097(95)00140-u -
Can Medications be Safely Withdrawn in Patients With Stable Chronic Heart Failure? Systematic Review and Meta-analysis
This systematic review and meta-analysis investigates the safety and outcomes of medication withdrawal in patients with stable chronic heart failure, revealing that discontinuation of RAAS inhibitors and beta-blockers is discouraged due to increased hospitalizations without mort…
DOI: 10.1016/j.cardfail.2014.04.013 -
The use of digitalis in heart failure
A comprehensive review of digitalis/digoxin in heart failure, detailing pharmacology, hemodynamic and neurohormonal effects, and a synthesis of randomized and observational studies showing symptomatic/hemodynamic benefits and reduced hospitalizations, but with inconsistent morta…
DOI: 10.1016/s0146-2806(96)80001-6